Dr. Olson's clinical efforts focus on pediatric hematopoietic stem cell transplantation (HSCT), with a specific emphasis on HSCT for patients with inherited and acquired bone marrow failure.
acute myeloid leukemia
Timothy Olson, MD, PhD
Daria Babushok, MD, PhD
Dr Daria Babushok is a physician-scientist and an Assistant Professor of Medicine in the Division of Hematology-Oncology at the University of Pennsylvania. Dr Babushok laboratory conducts basic and translational research focusing on the immune pathogenesis of acquired aplastic anemia and the development of clonal hematopoiesis in acquired aplastic anemia and other bone marrow failure disorders.
Peter Kurre, MD
With extended training in Pediatric Hematology, Oncology and Stem Cell Transplantation at Fred Hutchinson Cancer Research Center, Dr. Kurre’s clinical work is now focused on children with bone marrow failure. He strives to provide excellence in care for families and patients across a wide spectrum of inherited and acquired conditions that lead to loss of blood formation. As a Physician Scientist, both clinical and scientific goals of his work are therefore directed at improving understanding and broadening treatment options for patients with bone marrow failure. Dr. Kurre’s laboratory has longstanding expertise in Fanconi Anemia (FA), a genetic condition with prominent hematologic complications. With training in transplantation and hematopoietic stem cell biology, he hopes to improve our understanding of the progressive hematopoietic failure in patients with BMF and FA, and broaden diagnostic approaches, and develop next generation therapies.
- The role of germline genetic predisposition syndromes in the development of pediatric myelodysplastic syndrome and acute myeloid leukemia
- Patterns of HLA allele expression and clonal evolution in acquired aplastic anemia, and how these findings may serve as biomarkers for disease response as well as clues to the underlying immune basis of this disease
- Investigation of how intrinsic pathways governing hematopoietic stem cell niche function can be harnessed to improve the efficiency and durability of donor engraftment after hematopoietic stem cell transplantation, particularly in the context of bone marrow failure syndromes.
- Clinical trials of novel conditioning and T cell depletion strategies to improve survival and decrease allo-immune complications for patients with non-malignant hematologic disorders undergoing hematopoietic stem cell transplantation.
The long-term goal of the Babushok Laboratory to improve the outcomes of patients with bone marrow failure disorders through bench-to-bedside research aimed at elucidating mechanisms of hematopoietic failure and transforming this knowledge into rational therapies.
- Understand cause of stem cell losses in Fanconi Anemia.
- Failure of the hematopoietic system with stem cell losses is a near uniform occurrence in FA. The etiology remains unknown and we are using murine models to understand the underlying defect
- The role of FA proteins during hematopoietic development Hematopoietic development in bone marrow failure diseases is poorly understood and fetal deficits remain to be elucidated.
- As hematopoietic stem cells undergo maturation to an adult phenotype well after birth, therapeutic opportunities that focus on fetal characteristics may reveal additional therapeutic opportunities.
- The role of cell-derived extracellular vesicles in stem cell regulation.
- Cell derived vesicles are constitutively released by cells. The transmission of protein an RNA cargo to other cells in both paracrine and endocrine manner has revealed potent regulatory capacity. We are beginning to study their role in HSC regulation in several loss and gain of function models.